Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 May;106(1):3–8. doi: 10.1111/j.1476-5381.1992.tb14284.x

Morphine 6-glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret.

P I Thompson 1, S Bingham 1, P L Andrews 1, N Patel 1, S P Joel 1, M L Slevin 1
PMCID: PMC1907461  PMID: 1324067

Abstract

1. The emetic potencies of morphine and its metabolite morphine 6-glucuronide have been determined in the ferret by constructing dose-response curves for mean total retches and vomits for subcutaneous doses of 0.05 mg kg-1 to 5 mg kg-1. Morphine 6-glucuronide induced retching and vomiting at lower doses than morphine and at a maximal dose induced more retching and vomiting than morphine. 2. The emesis induced by both morphine and morphine 6-glucuronide was abolished by the preadministration of naloxone (0.5 mg kg-1 s.c.). 3. The 5-HT3 receptor antagonists granisetron and ondansetron (1 mg kg-1, s.c.) failed to abolish or reduce emesis induced by either compound. 4. At a high-dose (5 mg kg-1), morphine but not morphine 6-glucuronide failed to induce emesis and abolished the emesis induced by the cytotoxic drug, cyclophosphamide (200 mg kg-1, i.p.). 5. Preliminary pharmacokinetic studies of intravenous and subcutaneous morphine and morphine 6-glucuronide revealed that morphine 6-glucuronide accounts for less than 1% of the metabolic product of morphine in the ferret. Peak plasma levels of the two compounds after their subcutaneous administration were obtained within 10 min. The metabolic profile of morphine was not dose-dependent. There was no relationship between plasma level and emetic response for either compound.

Full text

PDF
3

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbott F. V., Palmour R. M. Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sci. 1988;43(21):1685–1695. doi: 10.1016/0024-3205(88)90479-1. [DOI] [PubMed] [Google Scholar]
  2. Andrews P. L., Davis C. J., Bingham S., Davidson H. I., Hawthorn J., Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol. 1990 Feb;68(2):325–345. doi: 10.1139/y90-047. [DOI] [PubMed] [Google Scholar]
  3. Bermudez J., Boyle E. A., Miner W. D., Sanger G. J. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer. 1988 Nov;58(5):644–650. doi: 10.1038/bjc.1988.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bhandari P., Andrews P. L. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret. Eur J Pharmacol. 1991 Nov 12;204(3):273–280. doi: 10.1016/0014-2999(91)90852-h. [DOI] [PubMed] [Google Scholar]
  5. Costello D. J., Borison H. L. Naloxone antagonizes narcotic self blockade of emesis in the cat. J Pharmacol Exp Ther. 1977 Oct;203(1):222–230. [PubMed] [Google Scholar]
  6. Florczyk A. P., Schurig J. E., Bradner W. T. Cisplatin-induced emesis in the Ferret: a new animal model. Cancer Treat Rep. 1982 Jan;66(1):187–189. [PubMed] [Google Scholar]
  7. Harris A. L. Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways. Lancet. 1982 Mar 27;1(8274):714–716. doi: 10.1016/s0140-6736(82)92625-3. [DOI] [PubMed] [Google Scholar]
  8. Hawthorn J., Ostler K. J., Andrews P. L. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q J Exp Physiol. 1988 Jan;73(1):7–21. doi: 10.1113/expphysiol.1988.sp003124. [DOI] [PubMed] [Google Scholar]
  9. Joel S. P., Osborne R. J., Slevin M. L. An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites. J Chromatogr. 1988 Sep 9;430(2):394–399. doi: 10.1016/s0378-4347(00)83176-x. [DOI] [PubMed] [Google Scholar]
  10. Miller R. R. Clinical effects of parenteral narcotics in hospitalized medical patients. J Clin Pharmacol. 1980 Apr;20(4 Pt 1):165–171. doi: 10.1002/j.1552-4604.1980.tb01692.x. [DOI] [PubMed] [Google Scholar]
  11. Oguri K., Ida S., Yoshimura H., Tsukamoto H. Metabolism of drugs. LXIX. Studies on the urinary metabolites of morphine in several mammlian species. Chem Pharm Bull (Tokyo) 1970 Dec;18(12):2414–2419. doi: 10.1248/cpb.18.2414. [DOI] [PubMed] [Google Scholar]
  12. Oguri K., Yamada-Mori I., Shigezane J., Hirano T., Yoshimura H. Enhanced binding of morphine and nalorphine to opioid delta receptor by glucuronate and sulfate conjugations at the 6-position. Life Sci. 1987 Sep 21;41(12):1457–1464. doi: 10.1016/0024-3205(87)90710-7. [DOI] [PubMed] [Google Scholar]
  13. Osborne R., Joel S., Trew D., Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther. 1990 Jan;47(1):12–19. doi: 10.1038/clpt.1990.2. [DOI] [PubMed] [Google Scholar]
  14. Pasternak G. W., Bodnar R. J., Clark J. A., Inturrisi C. E. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 1987 Dec 28;41(26):2845–2849. doi: 10.1016/0024-3205(87)90431-0. [DOI] [PubMed] [Google Scholar]
  15. Paterson S. J., Robson L. E., Kosterlitz H. W. Classification of opioid receptors. Br Med Bull. 1983 Jan;39(1):31–36. doi: 10.1093/oxfordjournals.bmb.a071787. [DOI] [PubMed] [Google Scholar]
  16. Shimomura K., Kamata O., Ueki S., Ida S., Oguri K. Analgesic effect of morphine glucuronides. Tohoku J Exp Med. 1971 Sep;105(1):45–52. doi: 10.1620/tjem.105.45. [DOI] [PubMed] [Google Scholar]
  17. Stables R., Andrews P. L., Bailey H. E., Costall B., Gunning S. J., Hawthorn J., Naylor R. J., Tyers M. B. Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev. 1987 Dec;14(3-4):333–336. doi: 10.1016/0305-7372(87)90026-0. [DOI] [PubMed] [Google Scholar]
  18. Svensson J. O., Rane A., Säwe J., Sjöqvist F. Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr. 1982 Jul 9;230(2):427–432. doi: 10.1016/s0378-4347(00)80494-6. [DOI] [PubMed] [Google Scholar]
  19. Watrous W. M., May D. G., Fujimoto J. M. Mechanism of the renal tubular transport of morphine and morphine ethereal sulfate in the chicken. J Pharmacol Exp Ther. 1970 Apr;172(2):224–229. [PubMed] [Google Scholar]
  20. Yoshimura H., Oguri K., Tsukamoto H. Metabolism of drugs. LXII. Isolation and identification of morphine glucuronides in urine and bile of rabbits. Biochem Pharmacol. 1969 Feb;18(2):279–286. doi: 10.1016/0006-2952(69)90205-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES